ECSP23093673A - Moduladores de los receptores acoplados a proteínas g - Google Patents
Moduladores de los receptores acoplados a proteínas gInfo
- Publication number
- ECSP23093673A ECSP23093673A ECSENADI202393673A ECDI202393673A ECSP23093673A EC SP23093673 A ECSP23093673 A EC SP23093673A EC SENADI202393673 A ECSENADI202393673 A EC SENADI202393673A EC DI202393673 A ECDI202393673 A EC DI202393673A EC SP23093673 A ECSP23093673 A EC SP23093673A
- Authority
- EC
- Ecuador
- Prior art keywords
- chemical entities
- gipr
- glp
- disorder
- disease
- Prior art date
Links
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 abstract 4
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 4
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 4
- 150000005829 chemical entities Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 4
- 230000008484 agonism Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 102000000072 beta-Arrestins Human genes 0.000 abstract 1
- 108010080367 beta-Arrestins Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Gyroscopes (AREA)
- Amplifiers (AREA)
- Holo Graphy (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación presenta entidades químicas (p. ej., un compuesto o una sal farmacéuticamente aceptable) que modulan (p. ej., agonizan o agonizan parcialmente o antagonizan) el receptor del péptido similar al glucagón tipo 1 (GLP-1R) y/o el receptor del polipéptido inhibidor gástrico (GIPR). Las entidades químicas son útiles, p. ej., para tratar una enfermedad, trastorno o afección en donde la modulación (p. ej., el agonismo, el agonismo parcial o el antagonismo) de las actividades de GLP-1R y/o de GIPR es beneficiosa para el tratamiento o la prevención de la patología subyacente y/o los síntomas y/o la progresión de la enfermedad, trastorno o afección. En algunas modalidades, la modulación da lugar a una mejora (p. ej., un aumento) de los niveles existentes (p. ej., niveles normales o inferiores a los normales) de la actividad (p. ej., la señalización) de GLP-1R y/o GIPR. En algunas modalidades, las entidades químicas descritas en el presente documento modulan aún más (p. ej., atenúan, desacoplan) la señalización de β-arrestina en relación con lo observado con el ligando nativo. La presente divulgación también presenta composiciones, así como otros métodos de uso y fabricación de dichas entidades químicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188342P | 2021-05-13 | 2021-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23093673A true ECSP23093673A (es) | 2024-01-31 |
Family
ID=82019613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202393673A ECSP23093673A (es) | 2021-05-13 | 2023-12-13 | Moduladores de los receptores acoplados a proteínas g |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12281149B2 (es) |
| EP (1) | EP4337682A2 (es) |
| JP (1) | JP2024517942A (es) |
| KR (1) | KR20240007251A (es) |
| CN (1) | CN117980325A (es) |
| AU (1) | AU2022272251A1 (es) |
| BR (1) | BR112023023559A2 (es) |
| CA (1) | CA3220005A1 (es) |
| CL (1) | CL2023003369A1 (es) |
| CO (1) | CO2023015805A2 (es) |
| CR (1) | CR20230530A (es) |
| DO (1) | DOP2023000247A (es) |
| EC (1) | ECSP23093673A (es) |
| GE (1) | GEAP202416419A (es) |
| IL (1) | IL308392A (es) |
| JO (1) | JOP20230291A1 (es) |
| MX (1) | MX2023013492A (es) |
| PE (1) | PE20240890A1 (es) |
| TW (1) | TW202313666A (es) |
| WO (1) | WO2022241287A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4281464A4 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| CN117980325A (zh) * | 2021-05-13 | 2024-05-03 | 卡莫特治疗学股份有限公司 | G-蛋白偶联受体的调节剂 |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| KR20250140132A (ko) * | 2023-01-18 | 2025-09-24 | 상하이 민웨이 바이오테크놀로지 씨오 엘티디 | 삼중 활성을 갖는 융합 단백질 및 그 용도 |
| TW202500575A (zh) * | 2023-05-21 | 2025-01-01 | 美商卡默療法股份有限公司 | 具有或不具有體重相關合併症之過重或肥胖成人之治療 |
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2026030653A1 (en) | 2024-07-31 | 2026-02-05 | Carmot Therapeutics Inc. | Synthesis of an intermediate and its use for the preparation of glp-1r/gipr agonists |
| WO2026027650A1 (en) | 2024-08-02 | 2026-02-05 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-(3-cyano-5-fluorophenyl)-2-methyl-propionic acid |
| CN119930843B (zh) * | 2025-01-22 | 2025-12-30 | 北京康乐卫士生物技术股份有限公司 | 具有glp和gip双重活性的融合蛋白及其应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| JP2002506792A (ja) | 1998-02-27 | 2002-03-05 | ノボ ノルディスク アクティーゼルスカブ | Ｎ末端修飾ｇｌｐ−１誘導体 |
| CN1495198A (zh) | 1998-12-07 | 2004-05-12 | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 胰高血糖素样肽-1的类似物 |
| KR20020015307A (ko) | 1999-02-26 | 2002-02-27 | 리처드 피. 버군 쥬니어 | Ｇ 단백질 결합 수용체 ６의 소형 분자 조절제 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1212120A2 (en) | 1999-09-07 | 2002-06-12 | Conjuchem, Inc. | Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents |
| US20030187023A1 (en) | 2000-07-17 | 2003-10-02 | Keiji Kubo | Sulfone derivatives, process for their production and use thereof |
| PL376733A1 (pl) | 2002-11-01 | 2006-01-09 | Takeda Pharmaceutical Company Limited | Środek do zapobiegania lub leczenia neuropatii |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| WO2004048363A1 (ja) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | イミダゾール誘導体、その製造法および用途 |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| GB0325644D0 (en) | 2003-11-04 | 2003-12-10 | Avidex Ltd | Immuno ihibitory pyrazolone compounds |
| EP1695961A4 (en) | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE |
| AU2004309271A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| US7585880B2 (en) | 2003-12-26 | 2009-09-08 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| EP1726580A4 (en) | 2004-03-15 | 2008-02-13 | Takeda Pharmaceutical | AMINOPHNYLPROPANO ACID DERIVATIVE |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| WO2006121860A2 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| JPWO2007013694A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | フェノキシアルカン酸化合物 |
| JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| CA2617969A1 (en) | 2005-08-10 | 2007-02-15 | Takeda Pharmaceutical Company Limited | Therapeutic agent for diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| ES2379661T3 (es) | 2006-06-27 | 2012-04-30 | Takeda Pharmaceutical Company Limited | Compuestos cíclicos condensados |
| WO2008021560A2 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
| JP5306818B2 (ja) | 2006-10-18 | 2013-10-02 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US8410087B2 (en) | 2006-10-19 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Indole compound |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| CA2677736A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| RU2012136450A (ru) | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
| SG185515A1 (en) | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| WO2011162989A2 (en) | 2010-06-24 | 2011-12-29 | Vanderbilt University | Glp-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| SG191252A1 (en) | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| EP2710031B9 (en) | 2011-05-18 | 2018-02-28 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for insulin resistance |
| WO2012167744A1 (en) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| US20150087586A1 (en) | 2012-03-29 | 2015-03-26 | Cebix, Inc. | Pegylated c-peptide |
| EP2916835A4 (en) | 2012-11-12 | 2016-07-27 | Redwood Bioscience Inc | COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE |
| WO2014088432A1 (en) | 2012-12-06 | 2014-06-12 | Callaghan Innovation Research Limited | Conjugate compounds |
| WO2014165240A1 (en) | 2013-03-13 | 2014-10-09 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For & On Behalf Of | Synbodies for detection of human norovirus |
| AU2014300503B2 (en) | 2013-06-28 | 2018-11-22 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| WO2015031268A1 (en) | 2013-08-26 | 2015-03-05 | Arizona Board Of Regents On Behalf Of Arizona State University | High affinity synbodies for influenza |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| ES2822994T3 (es) * | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Conjugados de incretina-insulina |
| CA2967077A1 (en) | 2014-11-14 | 2016-05-19 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| GB2551945B (en) | 2015-12-18 | 2021-09-08 | Heptares Therapeutics Ltd | Novel GLP-1 receptor agonist peptides |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| EA202092269A1 (ru) * | 2018-03-23 | 2020-12-14 | Кармот Терапьютикс, Инк. | Модуляторы сопряженных с g-белком рецепторов |
| TWI799680B (zh) | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| WO2022080986A1 (ko) | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| EP4204440A1 (en) | 2020-10-17 | 2023-07-05 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual agonists |
| CN114617956B (zh) | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| EP4269425A4 (en) | 2020-12-24 | 2024-11-27 | Hanmi Pharm. Co., Ltd. | NEW TRIPLE ACTIVATOR ACTIVATING ALL GLUCAGON, GLP-1 AND GIP RECEPTORS AND ITS USE |
| CN117980325A (zh) * | 2021-05-13 | 2024-05-03 | 卡莫特治疗学股份有限公司 | G-蛋白偶联受体的调节剂 |
| EP4392404A1 (en) | 2021-08-23 | 2024-07-03 | Eli Lilly and Company | Compounds and methods for liquid phase synthesis |
| WO2023030444A1 (zh) | 2021-09-02 | 2023-03-09 | 广东东阳光药业有限公司 | Glp-1/gip双靶多肽、融合蛋白及其应用 |
| WO2023089594A1 (en) | 2021-11-22 | 2023-05-25 | Sun Pharmaceutical Industries Limited | Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof |
-
2022
- 2022-05-13 CN CN202280048710.4A patent/CN117980325A/zh active Pending
- 2022-05-13 CR CR20230530A patent/CR20230530A/es unknown
- 2022-05-13 KR KR1020237042878A patent/KR20240007251A/ko active Pending
- 2022-05-13 WO PCT/US2022/029305 patent/WO2022241287A2/en not_active Ceased
- 2022-05-13 TW TW111118138A patent/TW202313666A/zh unknown
- 2022-05-13 AU AU2022272251A patent/AU2022272251A1/en active Pending
- 2022-05-13 US US17/744,540 patent/US12281149B2/en active Active
- 2022-05-13 PE PE2023003051A patent/PE20240890A1/es unknown
- 2022-05-13 JP JP2023569936A patent/JP2024517942A/ja active Pending
- 2022-05-13 EP EP22729907.0A patent/EP4337682A2/en active Pending
- 2022-05-13 BR BR112023023559A patent/BR112023023559A2/pt unknown
- 2022-05-13 CA CA3220005A patent/CA3220005A1/en active Pending
- 2022-05-13 GE GEAP202416419A patent/GEAP202416419A/en unknown
- 2022-05-13 IL IL308392A patent/IL308392A/en unknown
- 2022-05-13 MX MX2023013492A patent/MX2023013492A/es unknown
-
2023
- 2023-11-09 DO DO2023000247A patent/DOP2023000247A/es unknown
- 2023-11-10 CL CL2023003369A patent/CL2023003369A1/es unknown
- 2023-11-13 JO JOJO/P/2023/0291A patent/JOP20230291A1/ar unknown
- 2023-11-21 CO CONC2023/0015805A patent/CO2023015805A2/es unknown
- 2023-12-13 EC ECSENADI202393673A patent/ECSP23093673A/es unknown
-
2024
- 2024-07-18 US US18/777,223 patent/US20240383960A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240383960A1 (en) | 2024-11-21 |
| CN117980325A (zh) | 2024-05-03 |
| WO2022241287A3 (en) | 2022-12-29 |
| GEAP202416419A (en) | 2024-03-25 |
| DOP2023000247A (es) | 2024-03-28 |
| CL2023003369A1 (es) | 2024-05-17 |
| KR20240007251A (ko) | 2024-01-16 |
| JOP20230291A1 (ar) | 2023-11-13 |
| US12281149B2 (en) | 2025-04-22 |
| CR20230530A (es) | 2024-02-19 |
| IL308392A (en) | 2024-01-01 |
| BR112023023559A2 (pt) | 2024-02-06 |
| PE20240890A1 (es) | 2024-04-24 |
| CA3220005A1 (en) | 2022-11-17 |
| MX2023013492A (es) | 2024-02-29 |
| WO2022241287A2 (en) | 2022-11-17 |
| TW202313666A (zh) | 2023-04-01 |
| US20230151074A1 (en) | 2023-05-18 |
| AU2022272251A1 (en) | 2023-11-16 |
| EP4337682A2 (en) | 2024-03-20 |
| JP2024517942A (ja) | 2024-04-23 |
| CO2023015805A2 (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23093673A (es) | Moduladores de los receptores acoplados a proteínas g | |
| AR115016A1 (es) | Moduladores de receptores acoplados a la proteína g | |
| PE20212198A1 (es) | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) | |
| SA521431209B1 (ar) | مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1 | |
| CO2021012380A2 (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| PE20151770A1 (es) | Compuesto peptidico | |
| CL2017001760A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| BR112019010624A2 (pt) | agonistas duplos de glp-1/glp-2 acilados e composição | |
| ECSP20070185A (es) | Análogos novedosos de glp-1 | |
| Lange et al. | The distribution and physiological effects of the myoinhibiting peptides in the kissing bug, Rhodnius prolixus | |
| EA201592281A1 (ru) | Новые модуляторы рецептора glp-1 | |
| Šimo et al. | Invertebrate specific D1‐like dopamine receptor in control of salivary glands in the black‐legged tick Ixodes scapularis | |
| CL2019002112A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). | |
| AR112760A1 (es) | Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a) | |
| On et al. | Evolution of parathyroid hormone receptor family and their ligands in vertebrate | |
| CO2024013871A2 (es) | Terapia combinada para prevenir o tratar la obesidad | |
| Fieber | Neurotransmitters and neuropeptides of invertebrates | |
| PE20221271A1 (es) | Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas | |
| MX2019002437A (es) | Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon. | |
| Cornett et al. | A possible mechanism contributing to the synergistic action of vasotocin (VT) and corticotropin-releasing hormone (CRH) receptors on corticosterone release in birds | |
| Srinivasan et al. | [I10W] tigerinin-1R enhances both insulin sensitivity and pancreatic beta cell function and decreases adiposity and plasma triglycerides in high-fat mice | |
| Gallaher et al. | Recovery of viscerosensory innervation from the dorsal root ganglia of the adult rat following capsaicin‐induced injury | |
| Sabbatini et al. | C-type natriuretic peptide stimulates pancreatic exocrine secretion in the rat: role of vagal afferent and efferent pathways | |
| van den Munkhof et al. | The antipsychotic drug brexpiprazole reverses phencyclidine-induced disruptions of thalamocortical networks | |
| Watanabe et al. | Antagonistic effects of vasotocin and isotocin on the upper esophageal sphincter muscle of the eel acclimated to seawater |